

Vered Padler-Karavani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4674933/publications.pdf>

Version: 2024-02-01

57
papers

2,962
citations

201674

27
h-index

168389

53
g-index

61
all docs

61
docs citations

61
times ranked

2907
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration. <i>Nature Medicine</i> , 2022, 28, 283-294.	30.7	40
2	Placental colonization by <i>Fusobacterium nucleatum</i> is mediated by binding of the Fap2 lectin to placentally displayed Gal-GalNAc. <i>Cell Reports</i> , 2022, 38, 110537.	6.4	18
3	Synthetic heparan sulfate ligands for vascular endothelial growth factor to modulate angiogenesis. <i>Chemical Communications</i> , 2021, 57, 3516-3519.	4.1	9
4	Heparan Sulfate Mimetics Differentially Affect Homologous Chemokines and Attenuate Cancer Development. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3367-3380.	6.4	11
5	Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice. <i>IScience</i> , 2021, 24, 102479.	4.1	29
6	Biomolecular Recognition of the Glycan Neoantigen CA19-9 by Distinct Antibodies. <i>Journal of Molecular Biology</i> , 2021, 433, 167099.	4.2	5
7	Sulfation Code and Conformational Plasticity of l-Iduronic Acid Homo-Oligosaccharides Mimic the Biological Functions of Heparan Sulfate. <i>ACS Chemical Biology</i> , 2021, 16, 2481-2489.	3.4	10
8	Discovery of rare sulfated N-unsubstituted glucosamine based heparan sulfate analogs selectively activating chemokines. <i>Chemical Science</i> , 2021, 12, 3674-3681.	7.4	14
9	Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer. <i>Cancers</i> , 2020, 12, 2824.	3.7	14
10	Editorial: Human Antibodies Against the Dietary Non-human Neu5Gc-Carrying Glycans in Normal and Pathologic States. <i>Frontiers in Immunology</i> , 2020, 11, 1589.	4.8	1
11	Association between Neu5Gc carbohydrate and serum antibodies against it provides the molecular link to cancer: French NutriNet-SantA© study. <i>BMC Medicine</i> , 2020, 18, 262.	5.5	28
12	Rational design of universal immunotherapy for Tfr1-tropic arenaviruses. <i>Nature Communications</i> , 2020, 11, 67.	12.8	16
13	Glycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid. <i>Frontiers in Immunology</i> , 2020, 11, 21.	4.8	42
14	Specific Detection of Neu5Gc in Animal Tissues by Immunohistochemistry. <i>Methods in Molecular Biology</i> , 2020, 2110, 59-72.	0.9	2
15	Elicited and pre-existing anti-Neu5Gc antibodies differentially affect human endothelial cells transcriptome. <i>Xenotransplantation</i> , 2019, 26, e12535.	2.8	12
16	Nontypeable <i>Haemophilus influenzae</i> Has Evolved Preferential Use of N-Acetylneuraminic Acid as a Host Adaptation. <i>MBio</i> , 2019, 10, .	4.1	20
17	Generation of cattle knockout for galactose-1,3-galactose and N-glycolylneuraminic acid antigens. <i>Xenotransplantation</i> , 2019, 26, e12524.	2.8	30
18	Differential Recognition of Diet-Derived Neu5Gc-Neoantigens on Glycan Microarrays by Carbohydrate-Specific Pooled Human IgG and IgA Antibodies. <i>Bioconjugate Chemistry</i> , 2019, 30, 1565-1574.	3.6	12

#	ARTICLE	IF	CITATIONS
19	Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy. <i>ACS Nano</i> , 2019, 13, 2936-2947.	14.6	42
20	Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13069.	3.4	9
21	Presentation Mode of Glycans Affect Recognition of Human Serum anti-Neu5Gc IgG Antibodies. <i>Bioconjugate Chemistry</i> , 2019, 30, 161-168.	3.6	19
22	Engineered High-Specificity Affinity Reagents for the Detection of Glycan Sialylation. <i>FASEB Journal</i> , 2019, 33, 801.2.	0.5	3
23	Microarray Analysis of Oligosaccharide-Mediated Multivalent Carbohydrate-Protein Interactions and Their Heterogeneity. <i>ChemBioChem</i> , 2018, 19, 1170-1177.	2.6	14
24	ABO Antigens Active Tri- and Disaccharides Microarray to Evaluate C-type Lectin Receptor Binding Preferences. <i>Scientific Reports</i> , 2018, 8, 6603.	3.3	4
25	Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. <i>Transplantation Direct</i> , 2018, 4, e357.	1.6	12
26	Xenotransplantation: The Way beyond and Ahead toward Clinical Application. <i>Journal of Immunology Research</i> , 2018, 2018, 1-2.	2.2	1
27	Evolution of sialic acids: Implications in xenotransplant biology. <i>Xenotransplantation</i> , 2018, 25, e12424.	2.8	34
28	A combined computational-experimental approach to define the structural origin of antibody recognition of sialyl-Tn, a tumor-associated carbohydrate antigen. <i>Scientific Reports</i> , 2018, 8, 10786.	3.3	15
29	Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: Total antibody levels are associated with colorectal cancer risk. <i>PLoS ONE</i> , 2018, 13, e0197464.	2.5	45
30	High-Specificity Affinity Reagents for the Detection of Glycan Sialylation. <i>FASEB Journal</i> , 2018, 32, 544.16.	0.5	1
31	Profiling Anti-Neu5Gc IgG in Human Sera with a Sialoglycan Microarray Assay. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	23
32	Glycan microarray reveal induced IgGs repertoire shift against a dietary carbohydrate in response to rabbit anti-human thymocyte therapy. <i>Oncotarget</i> , 2017, 8, 112236-112244.	1.8	26
33	Glycan Microarray Reveal the Sweet Side of Cancer Vaccines. <i>Cell Chemical Biology</i> , 2016, 23, 1446-1447.	5.2	5
34	Screening of Neu5Ac(2-6)gal isomer preferences of siglecs with a sialic acid microarray. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 10812-10815.	2.8	6
35	Characterization of immunogenic Neu5Gc in bioprosthetic heart valves. <i>Xenotransplantation</i> , 2016, 23, 381-392.	2.8	63
36	Complexity and Diversity of the Mammalian Sialome Revealed by Nidovirus Virolectins. <i>Cell Reports</i> , 2015, 11, 1966-1978.	6.4	62

#	ARTICLE	IF	CITATIONS
37	Rapid evolution of binding specificities and expression patterns of inhibitory CD33-related Siglecs in primates. <i>FASEB Journal</i> , 2014, 28, 1280-1293.	0.5	71
38	Glycans in immune recognition and response. <i>Carbohydrate Research</i> , 2014, 389, 115-122.	2.3	95
39	Aiming at the sweet side of cancer: Aberrant glycosylation as possible target for personalized-medicine. <i>Cancer Letters</i> , 2014, 352, 102-112.	7.2	67
40	Quantum Dot Nanometal Surface Energy Transfer Based Biosensing of Sialic Acid Compositions and Linkages in Biological Samples. <i>Analytical Chemistry</i> , 2013, 85, 3864-3870.	6.5	35
41	Long-Term IgG Response to Porcine Neu5Gc Antigens without Transmission of PERV in Burn Patients Treated with Porcine Skin Xenografts. <i>Journal of Immunology</i> , 2013, 191, 2907-2915.	0.8	114
42	A Simple Method for Assessment of Human Anti-Neu5Gc Antibodies Applied to Kawasaki Disease. <i>PLoS ONE</i> , 2013, 8, e58443.	2.5	57
43	Cross-comparison of Protein Recognition of Sialic Acid Diversity on Two Novel Sialoglycan Microarrays. <i>Journal of Biological Chemistry</i> , 2012, 287, 22593-22608.	3.4	116
44	Specific inactivation of two immunomodulatory <i>SIGLEC</i> genes during human evolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9935-9940.	7.1	64
45	LC-MS Analysis of Polyclonal Human Anti-Neu5Gc Xeno-Autoantibodies Immunoglobulin G Subclass and Partial Sequence Using Multistep Intravenous Immunoglobulin Affinity Purification and Multienzymatic Digestion. <i>Analytical Chemistry</i> , 2012, 84, 2761-2768.	6.5	29
46	Human Xeno-Autoantibodies against a Non-Human Sialic Acid Serve as Novel Serum Biomarkers and Immunotherapeutics in Cancer. <i>Cancer Research</i> , 2011, 71, 3352-3363.	0.9	136
47	Potential impact of the non-human sialic acid <i>N</i> -glycolylneuraminic acid on transplant rejection risk. <i>Xenotransplantation</i> , 2011, 18, 1-5.	2.8	136
48	Implications of the presence of <i>N</i> -glycolylneuraminic acid in recombinant therapeutic glycoproteins. <i>Nature Biotechnology</i> , 2010, 28, 863-867.	17.5	316
49	Novel mechanism for the generation of human xeno-autoantibodies against the nonhuman sialic acid <i>N</i> -glycolylneuraminic acid. <i>Journal of Experimental Medicine</i> , 2010, 207, 1637-1646.	8.5	134
50	Sensitive and Specific Detection of the Non-Human Sialic Acid <i>N</i> -Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products. <i>PLoS ONE</i> , 2009, 4, e4241.	2.5	127
51	Evidence for a novel human-specific xeno-auto-antibody response against vascular endothelium. <i>Blood</i> , 2009, 114, 5225-5235.	1.4	107
52	Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease. <i>Glycobiology</i> , 2008, 18, 818-830.	2.5	297
53	Evidence for a human-specific mechanism for diet and antibody-mediated inflammation in carcinoma progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 18936-18941.	7.1	160
54	Biochemical support for the V-ATPase rotary mechanism: antibody against HA-tagged Vma7p or Vma16p but not Vma10p inhibits activity. <i>Journal of Experimental Biology</i> , 2003, 206, 3227-3237.	1.7	16

#	ARTICLE	IF	CITATIONS
55	Characterization of yeast V-ATPase mutants lacking Vph1p or Stv1p and the effect on endocytosis. Journal of Experimental Biology, 2002, 205, 1209-1219.	1.7	82
56	Characterization of yeast V-ATPase mutants lacking Vph1p or Stv1p and the effect on endocytosis. Journal of Experimental Biology, 2002, 205, 1209-19.	1.7	70
57	Features of V-ATPases that distinguish them from F-ATPases. FEBS Letters, 2001, 504, 223-228.	2.8	30